• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 20-F/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    3/28/25 4:15:08 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    FORM 20-F/A

    (Amendment No. 1)

     

    ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2024

     

    OR

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Commission File No.: 001-40303

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    (Exact name of registrant as specified in its charter)

     

    Translation of registrant’s name into English: Not applicable

     

    State of Israel 

    (Jurisdiction of incorporation or organization)

     

    2 Ha-Tidhar St.,

    Ra’anana, 4366504 Israel

    Tel: +972.4.6230333

    (Address of principal executive offices)

     

    Dagi Ben-Noon

    2 Ha-Tidhar St.,

    Ra’anana, 4366504 Israel

    Tel: +972.4.6230333

    (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Ordinary Shares, no par value   IINN   Nasdaq Capital Market
    Warrants to purchase Ordinary Shares   IINNW   Nasdaq Capital Market

     

    Securities registered or to be registered pursuant to Section 12(g) of the Act: None

     

    Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

     

    Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:

     

    24,252,096 ordinary shares, no par value, as of December 31, 2024.

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

     

    Yes ☐ No ☒

     

    If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.

     

    Yes ☐ No ☒

     

     

     

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

     

    Yes ☐ No ☒

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

     

    Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Emerging Growth Company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    †The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

     

    Yes ☐ No ☒

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.

     

    U.S. GAAP ☒

     

    International Financial Reporting Standards as issued by the International Accounting Standards Board ☐

     

    Other ☐

     

    If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

     

    ☐ Item 17 ☐ Item 18

     

    If this is an annual report, indicate by check mark whether the registrant is a shell company.

     

    Yes ☐ No ☒

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    We are filing this Amendment No. 1 (this “Amendment”) to our Annual Report on Form 20-F (the “Original Filing”) for the sole purpose of amending Item 18 of the Original Filing to amend the date of the auditor’s opinion located on page F-2 of this Amendment. For clarity, the audited financial statements as of and for the fiscal years ended December 31, 2024, 2023, and 2022 included in this Amendment No. 1 are unchanged from the audited financial statements included in the Original Filing.

     

    In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment No. 1 as Exhibits 12.1, 12.2, 13.1 and 13.2.

     

    Other than expressly set forth herein, this Amendment No. 1 does not, and does not purport to, amend or restate any other information contained in the Original Filing nor does this Amendment No. 1 reflect any events that have occurred after the Original Filing was filed.

     

     

     

     

        Page
    EXPLANATORY NOTE  
    PART III
     
    ITEM 17. FINANCIAL STATEMENTS 1
    ITEM 18. FINANCIAL STATEMENTS. 1
    ITEM 19. EXHIBITS. 1
    SIGNATURES 2

     

    i

     

     

    PART III

     

    ITEM 17. FINANCIAL STATEMENTS

     

    We have elected to provide financial statements and related information pursuant to Item 18.

     

    ITEM 18. FINANCIAL STATEMENTS

     

    The financial statements and the related notes required by this Item are included in this Amendment No. 1 to our annual report on Form 20-F beginning on page F-1.

     

    ITEM 19. EXHIBITS

     

    Number   Exhibit Description 
    1.1   Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-40303) filed on December 20, 2021 and incorporated herein by reference.)
    2.1   Description of Securities (filed as Exhibit 2.1 to Form 20-F on March 10, 2025, and incorporated herein by reference.)
    4.1   Form of Indemnification Agreement (filed as Exhibit 10.1 to Form F-1 (File No. 333-253920) filed on March 12, 2021 and incorporated herein by reference.)
    4.2   Amended and Restated Inspira Technologies Oxy B.H.N. Ltd. 2019 Equity Incentive Plan, (filed as Exhibit 99.1 to Form S-8 (File No. 333-285565) filed on March 5, 2025, and incorporated herein by reference.)
    4.3   Inspira Technologies Oxy B.H.N. Ltd. Compensation Policy for Company’s Executives, (filed as Exhibit 99.2 to Form 6-K (File No. 001-4030) filed on December 20, 2021, and incorporated herein by reference.)
    4.4   Form of Warrant Agent Agreement (filed as Exhibit 4.2 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference.)
    4.5   Form of Warrant (filed as Exhibit 4.4 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference.)
    4.6   Form of Amendment of Warrant Agreement by and between the Company and American Stock Transfer & Trust Company, LLC, dated August 8, 2022 (filed as Exhibit 4.6 to Form 20-F, filed on March 25, 2024 and incorporated herein by reference.)
    4.7   Form of Simple Agreement for Future Equity (filed as Exhibit 10.7 to Form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference.)
    4.8   Shareholder Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (filed as Exhibit 10.8 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference.)
    4.9   Form of Convertible Loan Agreement (filed as Exhibit 10.9 to Form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference.)
    4.10   Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2023, and incorporated herein by reference.)
    4.11   Warrant to Purchase Ordinary Shares (filed as Exhibit 4.7 to Form F-1 on May 9, 2024, and incorporated herein by reference.)
    4.12   Pre-Funded Ordinary Share Purchase Warrant (filed as Exhibit 4.1 to the Report of Foreign Private Issuer on Form 6-K on June 17, 2024, and incorporated herein by reference.)
    4.13   Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Report of Foreign Private Issuer on Form 6-K on June 17, 2024, and incorporated herein by reference.)
    4.14   Form of Ordinary Share Purchase Warrant (filed as Exhibit 99.3 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated herein by reference.)
    4.15   Pre-Funded Ordinary Share Purchase Warrant (filed as Exhibit 99.2 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated herein by reference.)
    4.16   Securities Purchase Agreement (filed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated herein by reference.)
    11.1(b)   Insider Trading Policy (filed as Exhibit 11.1(b) to Form 20-F on March 10, 2025, and incorporated herein by reference.)
    12.1*   Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.
    12.2*   Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.
    13.1%   Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350.
    13.2%   Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350.
    15.1*   Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.
    97.1   Inspira Technologies Oxy B.H.N. Ltd. Clawback Policy (filed as Exhibit 97.1 to Form 20-F, filed on March 25, 2024, and incorporated herein by reference).
    101*   The following financial information from the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024, formatted in XBRL (eXtensible Business Reporting Language): (i) Balance sheets as of December 31, 2024, December 31, 2023 and December 31, 2022; (ii) Statements of Comprehensive Loss as of December 31, 2024, December 31, 2023 and December 31, 2022; (iii) Statement of Changes in Shareholders’ Equity as of December 31, 2024, December 31, 2023 and December 31, 2022; (iv) Statements of Cash Flows as of December 31, 2024, December 31, 2023 and December 31, 2022; and (v) Notes to the financial statements.
    104*   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    * Filed herewith.
    % Furnished herewith.

     

    1

     

     

    SIGNATURES

     

    The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on Form 20-F filed on its behalf.

     

      INSPIRA TECHNOLOGIES OXY B.H.N. LTD.
         
    Date: March 28, 2025 By: /s/ Dagi Ben-Noon
        Dagi Ben-Noon
        Chief Executive Officer

     

    2

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

     

    TABLE OF CONTENTS

     

        Page
         
    Report of Independent Registered Public Accounting Firm (BDO Ziv Haft; Tel-Aviv, Israel; PCAOB#1185)   F-2
    Statements of balance sheet   F-3
    Statements of comprehensive loss   F-4
    Statements of changes in shareholders’ equity   F-5
    Statements of cash flows   F-8
    Notes to the financial statements   F-10 – F-33

     

    ______________________

    ________________

    ____________

     

    The amounts are stated in thousands of U.S. dollars

     

    F-1

     

     

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     

    To The Board of Directors and Shareholders of Inspira Technologies Oxy B.H.N. Ltd.

    Ha-Tidhar Street 2, Ra’anana, Israel

     

    Opinion on the Financial Statements 

     

    We have audited the accompanying balance sheets of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) as of December 31, 2024 and 2023, the related statements of comprehensive loss, changes in shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively, the “Financial Statements”). In our opinion, the Financial Statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

     

    Going Concern

     

    The accompanying Financial Statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the Financial Statements, the Company is at its development stage, therefore, it has suffered recurring losses and negative cash flows from operations since inception. As of December 31, 2024, the Company had incurred accumulated losses of $67 million. The Company’s operations have been funded substantially through issuance of shares and warrants. Considering the above, the Company’s dependency on external funding for its operations raises a substantial doubt about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are described in Note 1. The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.

      

    Basis for Opinion

     

    These Financial Statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these Financial Statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

     

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Financial Statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. 

     

    Our audits included performing procedures to assess the risks of material misstatement of the Financial Statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the Financial Statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the Financial Statements. We believe that our audits provide a reasonable basis for our opinion.

     

    We have served as the Company’s auditors since 2018.
    Tel-Aviv, Israel /s/ Ziv Haft
    March 6, 2025 Certified Public Accountants (Isr.)
      BDO Member Firm

      

    F-2

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    BALANCE SHEETS

    (US dollars in thousands)

     

          December 31,   December 31, 
       Note  2024   2023 
    ASSETS           
    Current Assets           
    Cash and cash equivalents     5,111    5,041 
    Deposits  3   668    2,320 
    Other current assets  4   587    432 
    Inventory  5   444    - 
    Total current assets      6,810    7,793 
    Non-Current Assets:             
    Right of use assets, net  9   761    1,011 
    Property, plant and equipment, net  6   499    506 
    Total non-current assets      1,260    1,517 
    Total Assets      8,070    9,310 
    LIABILITIES AND SHAREHOLDERS’ EQUITY             
    Current Liabilities:             
    Trade accounts payables      154    198 
    Other accounts payables  7   1,364    1,026 
    Lease liabilities  9   277    290 
    Financial liabilities at fair value  10   1,575    1,470 
    Total current liabilities      3,370    2,984 
    Non-Current Liabilities:             
    Lease liabilities  9   378    588 
    Total non- current liabilities      378    588 
    COMMITMENTS AND CONTINGENCIES  8   
     
        
     
     
    Shareholders’ Equity:             
    Ordinary shares, no par value:
    Authorized 100,000,000 ordinary shares as of December 31, 2024 and December 31, 2023;
    Issued and outstanding 24,252,096 ordinary shares as of December 31, 2024 and 15,652,176 shares as of December 31, 2023
          -     -  
    Share capital and additional paid in capital  11   70,896    61,259 
    Accumulated losses      (66,574)   (55,521)
    Total Shareholders’ Equity      4,322    5,738 
    Total liabilities and Shareholders’ Equity      8,070    9,310 

     

    These Financial Statements were authorized by the Board of Directors on March 6, 2025.

      

    The accompanying notes are an integral part of the Financial Statements.

     

    F-3

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    STATEMENTS OF COMPREHENSIVE LOSS

    (US dollars in thousands except for loss per share)

     

          Year ended
    December 31,
     
       Note  2024   2023   2022 
                    
    Research and development expenses  12   6,323    7,320    8,183 
    General and administrative expenses  13   4,185    4,063    5,375 
    Sales and marketing expenses  14   754    746    1,328 
    Other expenses (income)      5    4    7 
    Operating loss      11,267    12,133    14,893 
    Interest income from deposits      (172)   (318)   (192)
    Finance expenses (income), net  15   (42)   (529)   275 
    Loss before tax      11,053    11,286    14,976 
    Taxes on income      -    -    - 
    Total comprehensive and net loss      11,053    11,286    14,976 
                       
    Net loss per ordinary share, basic and diluted      (0.60)   (0.93)   (1.39)
    Weighted average number of ordinary shares outstanding basic and diluted      18,515,545    12,095,477    10,794,594 

     

    The accompanying notes are an integral part of the Financial Statements.

      

    F-4

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

    (US dollars in thousands)

      

    For the year ended December 31, 2024:

     

        Ordinary Share Capital         
       Number of shares   Share capital
    and
    Additional
    Paid in
    Capital
       Accumulated deficit   Total 
                     
    Balance as of January 1, 2024:   15,652,176    61,259    (55,521)   5,738 
                         
    Changes during the period:                    
    Issuance of ordinary shares, private warrants and pre-funded warrants, net   6,231,169    7,679    -    7,679 
    Exercise of options   19,048    2    -    2 
    Exercise of June 2024 pre-funded warrants into ordinary shares   1,709,760    2    -    2 
    Restricted share unit (“RSU”)vesting   594,943    -         - 
    Issuance of ordinary shares- advisor fees   45,000    62    -    62 
    Share-based compensation   -    1,892    -    1,892 
    Comprehensive and net loss   -    -    (11,053)   (11,053)
    Balance as of December 31, 2024   24,252,096    70,896    (66,574)   4,322 

     

    F-5

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

    (US dollars in thousands)

      

    For the year ended December 31, 2023:

     

       Ordinary Share Capital         
       Number of shares   Share capital
    and 
    Additional
    Paid in
    Capital
       Accumulated deficit   Total 
                     
    Balance as of January 1, 2023:   11,338,940    57,866    (44,235)   13,631 
                         
    Changes during the period:                    
                         
    Issuance of ordinary shares and private warrants, net   3,031,250    1,806    -    1,806 
    Issuance of placement agent warrants (Note 11.3)   -    131    -    131 
    Issuance of ordinary shares (pursuant to an at-the-market facility)   17,566    26    -    26 
    Exercise of share based payments   37,972    3    -    3 
    RSU vesting   1,226,448    -    -      
    Share-based compensation   -    1,427    -    1,427 
    Comprehensive and net loss   -    -    (11,286)   (11,286)
    Balance as of December 31, 2023   15,652,176    61,259    (55,521)   5,738 

      

    The accompanying notes are an integral part of the Financial Statements.

     

    F-6

     

      

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

    (US dollars in thousands)

     

    For the year ended December 31, 2022:

     

       Ordinary Share Capital         
       Number of shares   Share capital
    and
    Additional Paid in Capital
       Accumulated deficit   Total 
                     
    Balance as of January 1, 2022:   10,091,706    52,987    (29,259)   23,728 
                         
    Changes during the period:                    
    Exercise of share based payments   7,030    
    *
       -    - 
    RSU vesting   1,240,204    -    -    - 
    Share-based compensation   -    4,879    -    4,879 
    Comprehensive and net loss   -    -    (14,976)   (14,976)
    Balance as of December 31, 2022   11,338,940    57,866    (44,235)   13,631 

     

    (*) Less than thousand dollars

     

    The accompanying notes are an integral part of the Financial Statements.

     

    F-7

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    STATEMENTS OF CASH FLOW

    (US dollars in thousands)

     

       Year ended December 31 
       2024   2023   2022 
                 
    CASH FLOW FROM OPERATING ACTIVITIES:            
    Net loss   (11,053)   (11,286)   (14,976)
    Adjustments to reconcile net loss to net cash provided by operating activities:               
    Depreciation   171    111    54 
    Capital loss   5    -    - 
    Share based compensation expenses   1,892    1,427    4,879 
    Share based compensation – placement agent warrants   -    59    - 
    Evaluation of financial liability at fair value   47    (306)   (108)
    Expiration of financial liability   (11)   -    - 
    Issuance cost   -    205    - 
    Issuance of ordinary shares - advisor fees   62    -    - 
    Prepayments of lease liabilities   (9)   (7)   (51)
    Decrease (increase) in right of use assets, net   31    (5)   (99)
    Decrease (increase) in other current assets   (84)   190    99 
    (Decrease) increase in trade accounts payables   (44)   46    59 
    (Decrease) increase in other accounts payable   118    (190)   496 
    (Increase) decrease in inventory   (444)   -    - 
    Unrealized foreign exchange (gain) loss   (55)   65    438 
    Net cash used in operating activities   (9,374)   (9,691)   (9,209)
    CASH FLOW FROM INVESTING ACTIVITIES:               
    Purchase of property, plant, and equipment   (164)   (206)   (263)
    Change in deposits, net   1,652    4,800    (7,120)
    Net cash provided (used in) investing activities   1,488    4,594    (7,383)
    CASH FLOWS FROM FINANCING ACTIVITIES:               
    Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net   7,898    3,424    - 
    Exercise of options   2    3    - 
    Exercise of pre-funded warrants   2    -    - 
    Issuance of ordinary shares (issuances pursuant to an at-the-market facility)   -    26    - 
    Net cash provided by financing activities   7,902    3,453    - 
                    
    Effect of exchange rate changes on cash and cash equivalents   55    (65)   (438)
    Net increase (decrease) in cash and cash equivalents and restricted cash   16    (1,644)   (16,592)
    Cash, cash equivalents and restricted cash at the beginning of the period   5,130    6,839    23,869 
    Cash, cash equivalents and restricted cash at the end of the period   5,201    5,130    6,839 

      

    The accompanying notes are an integral part of the Financial Statements.

     

    F-8

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    STATEMENTS OF CASH FLOW

    (US dollars in thousands)

      

    APPENDIX A - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

     

    The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.

     

       Year ended December 31, 
       2024   2023   2022 
                 
    Cash and cash equivalents   5,111    5,041    6,783 
    Restricted cash   90    89    56 
    Total cash, cash equivalents and restricted cash shown in the statement of cash flows   5,201    5,130    6,839 

      

    APPENDIX B – NON-CASH TRANSACTIONS:

     

       Year ended December 31, 
       2024   2023   2022 
                 
    Other receivable in connection to December private placement   70    -    - 
    Accrued issuance expenses   (220)   -    - 
    Financial liability- placement agent fee (Note 10-A)   (69)   -    - 
    Share based compensation- placement agent warrants against additional paid in capital (Note 11)   (254)   (73)   - 
        (473)   (73)   - 

      

    APPENDIX C - AMOUNT PAID DURING THE PERIOD:

     

       Year ended December 31, 
       2024   2023   2022 
                    
    Interest paid   72    93    106 

      

    The accompanying notes are an integral part of the Financial Statements

      

    F-9

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 1 - GENERAL:

     

    1.Inspira Technologies Oxy B.H.N. Ltd (the “Company”) was incorporated in Israel and commenced its operations on February 27, 2018. The Company operates in the medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing related activities, and go-to-market activities of proprietary products and technologies. The Company is developing the following products:

     

    ●The INSPIRA ART (Augmented Respiratory Technology), which is a respiratory support technology targeted toward utilizing blood monitoring and direct blood oxygenation to boost patient saturation levels within minutes while the patient is awake. The aim is to provide an alternative to invasive mechanical ventilation, associated with high risks, complications, high costs and high mortality rates.
       
    ●The HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time and continuous blood parameter measurements, potentially reducing the need for intermittent blood samples from patients.
       
    ●The INSPIRA ART100 System, an advanced form of life support system, better known by the medical industry as a cardiopulmonary bypass system, has been designed for use in procedures requiring cardiopulmonary bypass for six hours or less.

     

    The Company’s INSPIRA™ ART100 system received U.S. Food and Drug Administration 510(k) regulatory clearance for cardiopulmonary bypass procedures and Israeli Medical Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures. The Company’s other products, including the INSPIRA™ ART and HYLA™ blood sensor, have not yet been tested or used in humans and have not been approved by any regulatory entity.

     

    2.On April 1, 2024, the Company entered into a purchase agreement with two investors in a registered direct offering (the “2024 April Offering”), pursuant to which the Company issued an aggregate of 1,339,285 of the Company’s ordinary shares (“Ordinary Shares”) at a purchase price of $1.232 per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $1,651. There were no issuance costs.

     

    3.On June 14, 2024, the Company entered into a purchase agreement with an individual private investor in a registered direct offering (the “2024 June Offering”), pursuant to which the Company issued: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share and (ii) pre-funded warrants (“June Pre-Funded Warrants”) to purchase up to 1,709,760 Ordinary shares, at a purchase price of $1.30, less $0.001 per June Pre-Funded Warrant. The net proceeds received by the Company from the 2024 June Offering were approximately $3,102, after deducting offering costs in cash, which totaled in approximately $343. In addition, the Company issued the placement agent in the 2024 June Offering (“June Placement Agent”) warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction to purchase up to 185,591 Ordinary Shares (the “June Placement Agent Warrants”). The fair value of the June Placement Agent Warrants on the issuance date was $254 and it was recorded as part of the issuance costs.

     

    4.On December 27, 2024, the Company entered into a purchase agreement with several investors in a private placement financing (the “December Private Placement”), pursuant to which the Company issued (i) an aggregate of 3,950,343 of the Company’s Ordinary Shares at a purchase price of $0.70 per share, and (ii) pre-funded warrants (the “December Pre-Funded Warrants”) to purchase up to 658,372 Ordinary shares, at a purchase price of $0.70, less $0.001 per December Pre-Funded Warrant. In addition, pursuant to a certain securities purchase agreement, the Company issued warrants to the investors to purchase up to an aggregate of 4,608,715 Ordinary Shares at an exercise price of $1.10 per share. The gross proceeds received by the Company from the December Private Placement were approximately $3,228, before deducting placement agent commissions and additional offering costs which totaled in approximately $233. In addition, The Company agreed to pay fees of 4% from the funds that may be received in an event of the exercise of the Company’s private warrants issued in December 2024 Private Placement, which created a financial liability in amount of $69 which is the total potential amount (Note 10-A).

     

    F-10

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 1 - GENERAL (CONT.):

      

    5.The accompanying financial statements (the “Financial Statements”) have been prepared assuming that the Company will continue as a going concern. To date, the Company is in its development stage. Therefore, the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2024, the Company had incurred accumulated losses of $67 million and expects to continue to fund its operations through fundings such as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.

     

    6.Our offices are located in Ra’anana, Israel. On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel declared war against Hamas and the Israeli military began to call-up reservists for an active duty. Other regional hostilities, since October 7, 2023, concurrently became more pronounced. This includes and has included a northern front war igniting between Israel and Hezbollah, which as of February 24, 2025 we are under a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances, and a continued conflict between Israel and the Houthi Movement in Yemen.

     

    As of the date of these Financial Statements, these events have no material impact on the Company’s operations.

      

    7.Although we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations and future growth prospects in that region. As a result of the crisis in Ukraine, both the U.S. and other countries have implemented sanctions against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our business, financial condition, results of operations, cash flows or the market price of our securities, including the potential for increased tensions between Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against certain companies and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.

     

    8.These Financial Statements were authorized by the Board of Directors on March 6, 2025.

     

    F-11

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

     

    The accompanying Financial Statements have been prepared in conformity with the U.S. GAAP. The significant accounting policies followed in the preparation of the Financial Statements are as follows:

     

    A. Use of estimates:

     

    The preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting period.

     

    Items subject to such estimates and assumptions include:

     

    ●stock-based compensation expense;
       
    ●fair value financial liabilities;
       
    ●recognition, measurement, and disclosure of contingent liabilities;
       
    ●Interest rate used for lease liability measurement.

     

    As of the date of issuance of the Financial Statements, the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s Financial Statements.

     

    B. Foreign Currency

     

    The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (“USD”). The Company’s funding and expected revenues are mostly in USD. Thus, the functional currency of the Company is in USD.

     

    Transactions and balances originally denominated in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency of the Company is USD. 

      

    F-12

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

     

    C. Property, Plant, and Equipment

     

    Property and equipment are stated at cost. Depreciation is computed based on the straight-line method, over the estimated useful life of the assets.

     

    Annual rates of depreciation are as follows:

     

       %
        
    Computers  33
    R&D equipment  20
    Furniture and office equipment  6-15
    Leasehold Improvements  10

      

    D. Inventory

     

    Inventories are stated at the lower of cost or net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items, technological obsolescence, excess inventories, discontinued products, and for market prices lower than cost, if any.

     

    The Company periodically evaluates the quantities on hand relative to historical and projected sales volume (which is determined based on an assumption of future demand and market conditions) and the age of the inventory. At the point of the loss recognition, a new lower cost basis for that inventory has been established.

     

    Cost is determined for all types of inventory using the moving average cost method plus indirect costs.

     

    E. Leases

     

    The Company implemented Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASU 2016-02”) using the modified retrospective approach for all lease arrangements as of such date. The Company leases office space and vehicles under operating leases.

     

    Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term.

     

    The lease liability was measured at the present value of the remaining lease payments, discounted using the Company’s incremental borrowing rate. The weighted-average rate applied was 9.60%. Right-of-use assets were measured at an amount equal to the lease liability.

     

    For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.

     

    F. Research and Development Costs.

     

    Research and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.

     

    G. Government Grants

     

    The Company receives royalty-bearing grants from the Israeli Innovation Authority (“IIA”) for approved research and development projects Under Israeli law, royalties on the revenues derived from products and services developed using such grants, are payable to the Israeli Government.

     

    The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate (“SOFR”) per year (SOFR is a benchmark interest rate which replaced LIBOR).

     

    F-13

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

     

    The amounts of grants received and recorded into income should be disclosed for each period presented. The research and development grants are presented in the statement of operations as an offset to related research and development expenses. Companies are required to pay royalties in connection with such grants at specified rates, up to the total dollar-linked amount of such grants. research and development (“R&D”). The Company did not generate sales as of December 31, 2024; therefore, no liability was recorded in these Financial Statements.

      

    H. Finance Income and Expenses.

     

    Finance income is composed of interest on deposits and revaluation of financial liabilities at fair value, while finance expenses are composed of the revaluation of certain financial liabilities at fair value, bank charges and net currency exchange rates differences.

     

    I. Current Taxes

     

    The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward losses.

     

    J. Share-Based Compensation.

     

    Share-based compensation expenses related to employees, directors and subcontractors’ options or restricted share units (“RSU”) which recognized based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using the graded vesting method.

     

    The Company recognizes compensation expense for grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development, selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.

     

    All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued.

     

    K. Warrants and Pre-Funded Warrants

     

    The Company issues warrants and pre-funded warrants as part of its financing activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder to purchase a specified number of the Company’s Ordinary Shares at a predetermined exercise price. Warrants and pre-funded warrants issued by the Company may have various terms, including expiration dates, exercise prices, and conditions.

     

    The Company classifies warrants as either equity or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (“ASC”) 815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as equity if they meet the criteria for equity classification outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.

     

    L. Severance

     

    Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company’s pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963 (“Section 14”), the Company’s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance pay.

     

    F-14

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

     

    M. Basic and Diluted Loss Per Share

     

    Basic and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares and pre-funded warrants outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants issued during the year, if applicable.

     

    N. Fair Value Measurements

     

    The Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (“FASB”), ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

     

    Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

     

    Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

     

    Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.

     

    This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

     

    The fair value of cash is based on its demand value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities are estimated to be equal to their fair value due to the short-term nature of these instruments.

     

    O. Concentration of Credit Risk

     

    The Company maintains certain cash balances in a well-known Israeli banks and U.S based banks.

     

    Part of the Company’s operating expenses are denominated in New Israeli Shekel (“NIS”), and therefore, subject to foreign currency risk.

     

    F-15

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

      

    NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

     

    P. Cash and Cash Equivalent

     

    Cash equivalents are highly liquid investments that are readily convertible into cash, typically with an original maturity of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

     

    Restricted cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented restricted cash separately from cash and cash equivalents in the balance sheets.

     

    Bank deposits with maturities of more than three months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at cost which approximates market value. As of December 31, 2024 and December 31, 2023, the Company had short-term deposits in the amounts of $0.7 million and $2.3 million, respectively.

     

    Q. Segment Information

     

    The Company has a single operating and reportable segment. The Company’s chief operating decision maker (“CODM”), who is the Chief Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the accompanying Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.

     

    R. New accounting Pronouncements

     

    Accounting Standards Adopted in 2024

     

    In March 2023, the FASB issued Accounting Standard Updated No. 2023-01 “Lease (Topic 842)”. Topic 842 requires that entities determine whether a related party arrangement between entities under common control (hereinafter referred to as a common control arrangement) is a lease. If the arrangement is determined to be a lease, an entity must classify and account for the lease on the same basis as an arrangement with an unrelated party (on the basis of legally enforceable terms and conditions).That represents a change from the requirements of Topic 840, Leases, which required that an entity classify and account for an arrangement on the basis of economic substance when those terms and conditions were affected by the related party nature of the arrangement. The amendments in this Update affect all lessees that are a party to a lease between entities under common control in which there are leasehold improvements. The amendments apply to all entities (that is, public business entities, private companies, not-for-profit. The Company adopted ASU 2023-01 on January 1, 2024, its adoption did not have a material impact on the Financial Statements and related disclosures.

     

    In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions” which clarifies that contractual restrictions on equity security sales are not considered part of the security unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized and measured as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal years beginning after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects that ASU 2022-03 will not have a material impact on its Financial Statements and related disclosures.

     

    F-16

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

      

    NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

     

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU’s amendments are effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.

     

    Accounting Pronouncements Issued but Not Yet Adopted

     

    In December 2023, the FASB issued ASU 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires entities to subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting period. In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU’s amendments are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15, 2024, including interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We do not expect this pronouncement to have a material impact on our Financial Statements.

     

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU’s amendments are effective for all entities that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of this pronouncement on our disclosures.

     

    NOTE 3 – DEPOSITS:

     

    The Company’s deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits bear annual interest. Interest earned is recorded as finance income, net in the statement of operations during the years for which the Company held short-term deposits.

     

    As of December 31, 2024, the Company had a deposit in NIS at Bank Leumi in the amount of $668, including interest that bore a fixed annual interest of 4.108%.

     

    As of December 31, 2023, the Company had a deposit in USD at Bank Leumi in the amount of $2,040, including interest that bore fixed annual interest of 6.18% and a deposit in NIS in the amount of $280 that bore fixed annual interest of 4.85%.

     

    F-17

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

      

    NOTE 4 - OTHER CURRENT ASSETS:

     

       December 31,
    2024
       December 31,
    2023
     
    Prepaid expenses   240    176 
    Institutions   183    164 
    Restricted Cash   90    89 
    Others   74    3 
    Total   587    432 

     

    NOTE 5 - INVENTORY

     

       December 31,
    2024
       December 31,
    2023
     
    Raw materials   96         - 
    Work in progress   55    - 
    Finished good (*)   293    - 
    Total   444    - 

     

    (*) As of December 31, 2024, seven INSPIRA ART100 systems and seven carts were in the course of being delivered to a distributor in the U.S.

     

    NOTE 6 - PROPERTY AND EQUIPMENT, NET:

     

    For the year ended December 31, 2024:

     

       Computers   Leasehold
    improvements
       R&D
    equipment
       Furniture
    and office
    equipment
       Total 
    Cost                    
    At January 1, 2024   172    36    381    116    705 
    Additions   10    -    154    -    164 
                              
    At December 31, 2024   182    36    535    116    869 
                              
    Accumulated depreciation                         
                              
    At January 1, 2024   102    8    73    16    199 
    Depreciation   44    4    116    7    171 
                              
    At December 31, 2024   146    12    189    23    370 
    Net book value:                         
    As of December 31, 2024   36    24    346    93    499 

     

    F-18

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 6 - PROPERTY AND EQUIPMENT, NET (CONT.):

     

    For the year ended December 31, 2023:

     

       Computers   Leasehold
    improvements
       Development
    equipment
       Furniture
    and office
    equipment
       Total 
    Cost                    
    At January 1, 2023   121    33    229    116    499 
    Additions   51    3    152    
    -
        206 
                              
    At December 31, 2023   172    36    381    116    705 
                              
    Accumulated depreciation                         
                              
    At January 1, 2023   51    4    25    8    88 
    Depreciation   51    4    48    8    111 
                              
    At December 31, 2023   102    8    73    16    199 
    Net book value:                         
    As of December 31, 2023   70    28    308    100    506 

      

    NOTE 7 - OTHER ACCOUNTS PAYABLE:

     

       December 31,
    2024
       December 31,
    2023
     
             
    Employees’ salaries and related liabilities   414    388 
    Related parties   421    354 
    Accrued expenses   508    267 
    Other   21    17 
    Total   1,364    1,026 

     

    NOTE 8 - COMMITMENTS AND CONTINGENCIES

     

    A. Royalties to the IIA:

     

    In September 2019, the IIA approved a grant to the Company for the development of intravenous blood oxygenation system for an aggregate budget of NIS 4,880,603 (approximately $1,500). The IIA committed to fund 60% of the approved budget. Eventually the project budget concluded in the aggregate amount of NIS 4,623,142 (approximately $1,333). The program is for the period beginning October 2019 through November 2020. From 2019 to 2021, the Company received total funds in the amount of NIS 2,773,885 (approximately $809) from the IIA, which were recorded as IIA participation and were deducted from R&D expenses.

     

    F-19

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 8 - COMMITMENTS AND CONTINGENCIES (CONT.):

     

    In October 2023, the IIA approved a grant to support another development project of the Company at an aggregate budget of NIS 3,850,869 (approximately $1,062). The IIA committed to fund 40% of the approved budget.

     

    The program is for the period beginning January 2024 through March 2025, and as of December 31, 2024, the Company received total funds in the amount of NIS 1,062,049 (approximately $286) from the IIA, which were recorded as IIA participation and were deducted from the R&D expenses.

     

    According to the agreements with the IIA, The Company will pay royalties of 3% of future sales up to an amount equal to the accumulated grant received linked to the U.S. dollar and bearing interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful completion of the Company’s R&D programs and generating sales. The Company has no obligation to repay these grants if the R&D programs fail, are unsuccessful or aborted or if no sales are generated.

     

    The Company had not generated sales as of December 31, 2024; therefore, no liability was recorded in these Financial Statements. As of December 31, 2024, the maximum obligation with respect to the grants received from the IIA, contingent upon entitled future sales, is $1,095 plus SOFR interest.

     

    The Company has obligations regarding know-how, technology, or products, not to transfer the information, rights thereon and production rights which derive from the research and development without the IIA Research Committee approval.

     

    B. Legal Claims

     

    In the normal course of business, various legal claims and other contingent matters may arise. Management believes that any liability that may arise from such matters would not have a material adverse effect on the Company’s results of operations or financial condition as of and for the years ended December 31, 2024, and 2023.

     

    On December 12, 2021, the Company terminated its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company’s Chief Scientific Officer since March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the Company,, as well as a Statement of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged certain deficiencies in the Company’s Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr. Nussinovitch is seeking renumeration and the issuance of Ordinary Shares.

     

    On July 19. 2023, a partial hearing about the labor dispute was held, in which the parties were required by the court to file their positions on a stay of the proceeding pending the decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing about the civil case was held. During the hearing, the court suggested the parties consider the possibility of resolving the case through an out-of-court arrangement or mediation. The parties agreed to a mediation process which did not succeed. On January 7, 2025, Mr. Nussinovitch filed a motion to amend his Statement of Claim, requesting to modify the requested relief. Instead of the original remedies sought, Mr. Nussinovitch now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase all of his rights and shares in the Company at their average value from the date of the Company’s initial public offering until the date of the general meeting held on December 17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch’s motion to amend and instructed him to notify whether he wishes to withdraw his original claim or maintain it. As of the date of these Financial Statements, Mr. Nussinovitch has not yet provided his response. 

     

    As of the date of these Financial Statements, the Company believes that the claims will result in no payments by the Company.

     

    F-20

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 9 – LEASE LIABILITIES

     

    Lease Commitments – Operating Leases:

     

    In September 2021, the Company entered into a lease agreement for its facilities in Ra’anana, Israel. The lease agreement is for a period of 69 months commencing September 1, 2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS 500,000, (approximately $153). This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9) if the Company terminates the agreement after 45 months of rent. The Company is reasonably certain that it will not exercise the termination option. The annual lease payment, including management fees, as of December 31, 2024, is approximately NIS 69,000 ($17.5). As security for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract.

     

    The Company has various operating leases for vehicles that expire through 2027. The Company leases vehicles for approximately three-year periods from multiple different leasing companies and from time to time increases or decreases the number of leased vehicles according to its current needs. The leased vehicles are used by the Company’s headquarters staff and other employees whose employment agreements include an obligation on the Company to provide a vehicle. The agreements with the leasing companies include termination options, allowing for early cancellation by paying a penalty of up to 400% of the monthly costs. The Company is reasonably certain that it will not exercise this option or that the employee will bear the cost for early termination.

     

    The total expenses related to the leases were $390 for the year ended December 31, 2024, and $371 for the year ended December 31, 2023.

     

    The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate based on the information available at the date of determining the present value of the lease payments.

     

    The Company’s incremental borrowing rate is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located.

     

    The Company has various operating leases for vehicles that expire through 2027. Below is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of December 31, 2024, and 2023:

      

      

    December 31,

    2024

       December 31,
    2023
     
             
    Operating lease liabilities, current   277    290 
    Operating lease liabilities long-term   378    588 
    Total operating lease liabilities   655    878 
               
    Weighted Average of Remaining Lease Term   2.52    3.33 
    Weighted-average discount rate - operating leases   9.92%   9.6%

      

    F-21

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

      

    NOTE 9 – LEASE LIABILITIES (CONT.):

     

    Lease payments for the Company’s right-of-use assets over the remaining lease periods as of December 31, 2024, are as follows: 

     

    Year ended December 31,   U.S. dollars
    in thousands
     
         
    2025   326 
    2026   254 
    2027   154 
          
    Total undiscounted lease payment   734 
    Less: Interest (*)   (79)
    Present value of lease liabilities   655 

     

    (*) Future lease payments were discounted by 7.98%-15.78% interest rate.

      

    NOTE 10 – FINACIAL LIABILITIES AT FAIR VALUE:

     

      

    December 31,

    2024

      

    December 31,

    2023

     
             
    Financial liability (A)   69    11 
    Private warrants (B)   1,506    1,459 
    Total   1,575    1,470 

      

    A Financial Liability

     

    1.The Company agreed to pay fees of 7% from funds that may be received in an event of exercise of the Company’s tradable warrants which created a financial liability. The financial liability was designated to be measured at fair value through profit or loss. As of December 31, 2023, the fair value of the financial liability was $11. Such agreement expired in July 2024 and as of December 31, 2024, the financial liability amounted to null.

     

    2.The Company agreed to pay fees of 4% from the funds that will be received in an event of exercise of part of the Company’s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability on the total potential amount which is $69 as of December 31, 2024 (Note 10).

     

    The financial liability fair value as of December 31, 2024, and 2023 is $69 and $11 respectively.

     

    F-22

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

      

    NOTE 10 – FINACIAL LIABILITIES AT FAIR VALUE (CONT.):

     

    B Private warrants

     

    On December 26, 2023, the Company entered into a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (the “Private Warrants”). The Private Warrants were exercisable immediately upon issuance and will expire three and a half years following their issuance.

     

    The Private Warrants include cashless exercise mechanism, according to the terms specified in the agreement.

     

    The Private Warrants may create obligation to transfer cash to the investors at fundamental transactions within the Black Scholes option pricing framework.

     

    Therefore, the Company accounts for the Private Warrants as financial liability instruments that are measured at fair value and recognized financial expenses or income through profit and loss.

     

    The company measured fair value by using Black-Scholes option pricing model;

     

    The key inputs that were used in the private warrants fair value as of December 31, 2023, were:

     

    ●risk-free interest rate 4.00%
       
    ●expected volatility 66.63%
       
    ●expected dividend yield of 0%
       
    ●expected term of warrants – 3.5 years.

     

    The key inputs that were used in the private warrants fair value as of December 31, 2024, were:

     

    ●risk-free interest rate 4.26%
       
    ●expected volatility 88.61%
       
    ●expected dividend yield of 0%
       
    ●expected term of warrants – 2.5 years.

     

    The fair value of the Private Warrants as of December 31, 2024 and 2023 was $1,506 and $1,459 respectively.

     

    NOTE 11 – SHAREHOLDERS’ EQUITY:

     

    A. Share capital:

     

       Number of shares as of
    December 31, 2024
       Number of shares as of
    December 31, 2023
     
       Authorized   Issued and outstanding   Authorized   Issued and outstanding 
    Ordinary shares   100,000,000    24,252,096    100,000,000    15,652,176 

      

    1.During the year ended December 31, 2022, the Company issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection to certain option exercises.

     

    2.On April 4, 2023, the Company entered into a sales agreement (the “Sales Agreement”) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (“ATM”). In 2023, the Company sold 17,566 Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and the associated ATM, effective immediately.

     

    F-23

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 11 - SHAREHOLDERS’ EQUITY (CONT.):

     

    3.On December 26, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor in a registered direct offering (the “Registered Direct Offering”), pursuant to which the Company issued (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, (ii) pre-funded warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note 10-B).

     

    The Company concluded that the Pre-Funded Warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company concluded that the pre-funded warrants are indexed to the Company’s own stock and meet the conditions for equity classification, and thus should be presented within equity.

     

    As for the common warrants, the Company concluded that they should be classified as a liability under ASC 815-40, as they are not indexed to the Company’s own stock.

     

    The pre-funded warrants were exercised on the same day and the day after the transaction in full in an exercise price of $0.001 per share and the Company issued 1,656,250 additional Ordinary Shares.

     

    The aggregate proceeds received by the Company from the Registered Direct Offering were approximately $3,424, after deducting underwriting discounts and commissions and additional cash offering costs totaled in approximately $454.

     

    The Company issued the placement agent in the Registered Direct Offering a number of warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, total to 212,188 warrants to purchase up to 212,188 Ordinary Shares, were issued (the “Placement Agent Warrants”).

     

    The Placement Agent Warrants were substantially on the same terms as the Warrants issued to the investor in the offering, except an exercise price of $1.60 per share. The Placement Agent Warrants were exercisable immediately upon issuance and will expire five years following their issuance. The Company accounts for the Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $131.

     

    Those cash and non-cash issuance costs were accounted proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability versus equity in the Registered Direct offering.

     

    4.During the year ended December 31, 2023, the Company issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection with option exercises.

     

    5.On April 1, 2024, the Company completed its 2024 April Offering, whereby the Company sold 1,339,285 Ordinary Shares at a purchase price of $1.232 per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $1,651.

     

    6.On May 20, 2024, the Company issued warrant to purchase 220,000 Ordinary Shares to a service provider, at an exercise price of $2.25 per share. These warrants are immediately exercisable and are due to expire six months from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $125. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.

     

    7.On June 14, 2024, the Company completed its 2024 June Offering, whereby the Company sold: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share, and (ii) June Pre-Funded Warrants to purchase up to 1,709,760 Ordinary Shares, at a purchase price of $1.30, less $0.001 per June Pre-Funded Warrant. Each June Pre-Funded Warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. The June Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the June Pre-Funded Warrants are exercised in full. As of December 31, 2024, all of the June Pre-Funded warrants were exercised, and the company issued 1,709,760 Ordinary Shares.

     

    Net proceeds received by the Company from the 2024 June Offering were approximately $3,102, after deducting cash offering costs which were approximately $343.

      

    F-24

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 11 - SHAREHOLDERS’ EQUITY (CONT.):

     

    The Company also received $2 from an exercise of the June Pre-Funded Warrants.

     

    The Company concluded that the June Pre-Funded Warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the June Pre-Funded Warrants are indexed to the Company’s own stock and meet the conditions for equity classification, and thus should be presented within equity.

     

    The Company issued the June Placement Agent in the agreement warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction. A total to 185,591 warrants to purchase up to 185,591 Ordinary Shares were issued. The June Placement Agent Warrants had an exercise price of $1.56 per share. The June Placement Agent Warrants were exercisable immediately upon issuance and will expire four years following their issuance.

     

    The Company accounting treatment for the June Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the June Placement Agent Warrants at the issuance date was $254.

     

    The cash and non-cash issuance costs were recorded against additional paid in capital, due to the classification of the Ordinary Shares and the June Pre-Funded Warrants as equity instrument.

     

    8.On June 30, 2024, the Company issued 45,000 Ordinary Shares to an advisor in connection with a consulting service agreement.

     

    9.On December 27, 2024, the Company completed its December Private Placement, whereby the Company sold (i) 3,950,343 Ordinary Shares and December Private Warrants to purchase up to 3,950,343 Ordinary Shares at a purchase price of $0.70 per unit, and (ii) December Pre-Funded Warrants to purchase up to 658,372 Ordinary Shares and December Private Warrants to purchase up to 658,372 Ordinary Shares, at a purchase price of $0.70, less $0.001 per unit with December Pre-Funded Warrant. Each December Pre-Funded Warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. Each December Private Warrant is exercisable for one Ordinary Share at an exercise price of $1.10 per share. The December Private Warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The December Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the December Pre-Funded Warrants are exercised in full. As of December 31, 2024, none of the December Pre-Funded warrants or the December Private Warrants were exercised.

      

    F-25

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 11 - SHAREHOLDERS’ EQUITY (CONT.):

     

    The Company concluded that the December Private Warrants and December Pre-Funded Warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the December Private Warrants and December Pre-Funded Warrants are indexed to the Company’s own stock and meet the conditions for equity classification, and thus should be presented within equity.

     

    The gross proceeds received by the Company from the December Private Offering were approximately $3,228, before deducting underwriting discounts and commissions and additional cash offering costs totaled approximately $233. In addition, the Company agreed to pay fees of 4% from the funds that may be received in an event of exercise of part of the Company’s private warrants issued in December 2024 Private Placement which created a financial liability in amount of $69 which is the total potential amount (Note 10-A).

     

    The cash and non-cash issuance costs were recorded against additional paid in capital.

     

    10.During the year ended December 31, 2024, the Company issued an aggregate amount of 594,943 Ordinary Shares in connection with vested RSUs and an additional 19,048 Ordinary Shares in connection with option exercises.

      

    B. Warrants reserves -Composition and movements:

     

    1.The following table reconciles the movement in warrants outstanding at the beginning and end of the period:

     

       Number of
    Warrants
       Weighted-average exercise price  

    Weighted average remaining contractual term

    (in years)

     
                 
    Balance as of December 31, 2023   3,333,283    5.47    1.83 
                    
    Issued   7,382,438    1.22    1.93 
    Exercised   (1,709,760)   0.001    - 
    Expired   (1,277,350)   5.25    0.54 
    Balance as of December 31, 2024   7,728,611    4.14    1.63 

      

    2.The following table summarizes information about the Company’s outstanding warrants as of December 31, 2024

     

    Exercise Price

     

    Warrants
    outstanding as of

    December 31, 2024

       Expiration date
    5.5   1,640,455   15/07/2026
    5.5   277,835   15/07/2025
    6.875   145,455   15/01/2027
    1.6   212,188   28/06/2027
    1.56   185,591   18/06/2028
    1.1   4,608,715   30/06/2026
    0.001   658,372   Until fully exercised
    Balance as of December 31, 2024   7,728,611    

     

    F-26

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 11 - SHAREHOLDERS’ EQUITY (CONT.):

     

    C. Loss per share:

     

    Loss per share has been calculated using the weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit for the period as follows:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
                 
    Loss for the period   11,053    11,286    14,976 
    Total number of Ordinary Shares   24,252,096    15,652,176    11,338,940 
    Weighted average number of Ordinary Shares and pre-funded warrants   18,515,545    12,095,477    10,794,594 
                    
    Basic and diluted loss per share   (0.60)   (0.93)   (1.39)

     

    NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
                 
    Salary and related expenses   4,079    4,429    3,458 
    Materials and related expenses   812    1,365    1,082 
    Share based payment   801    663    2,392 
    Depreciation   371    291    188 
    Subcontractors   340    304    850 
    IIA participation   (286)   -    - 
    Other   206    268    213 
    Total   6,323    7,320    8,183 

     

    F-27

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
                 
    Professional fees   1,758    1,432    1,500 
    Salary and related expenses   808    766    716 
    Share-based payment   716    675    1,984 
    Director fees   239    241    239 
    Insurance expenses   196    300    557 
    Office maintenance   135    129    102 
    Depreciation   117    115    104 
    Travel abroad   104    100    105 
    Fundraising expenses   -    260    - 
    Others   112    45    68 
    Total   4,185    4,063    ,5375 

     

    NOTE 14 - SALES AND MARKETING EXPENSES:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
                 
    Salary and related expenses   266    248    282 
    Share-based payment   250    89    503 
    Professional fees   187    348    527 
    Other   51    61    16 
        754    746    1,328 

      

    NOTE 15– FINANCIAL (INCOME) AND EXPENSES:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
                 
    Revaluation of financial liabilities at fair value through profit or loss   36    (306)   (108)
    Foreign currency transaction income   (77)   (233)   530 
    Finance expense in respect of lease liability   -    -    (143)
    Others   (1)   10    (4)
    Total expenses (Income)   (42)   (529)   275 

     

     

    F-28

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

      

    NOTE 16 - TAXES ON INCOME:

     

    A.Taxes on income:

     

    The Israeli corporate tax rate was 23% in 2024 and 2023.

     

    B.Net operating losses carry forwards:

     

    Carryforward tax losses of the Company as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was recorded against the potential future tax benefits.

     

    Carryforward tax losses of the Company as of December 31, 2024, amounted to approximately $29,000; however, a full valuation allowance of $8,000 was recorded against the potential future tax benefits.

     

    The deferred tax assets and liabilities are composed of the following:

      

       December 31,
    2024
       December 31,
    2023
     
    Deferred tax assets:        
    Net operating loss carryforward   6,739    5,519 
    Accrued expenses   97    80 
    R&D temporary differences   1,218    1,335 
    Fund raising costs 2023   35    70 
    Operating lease liability   8    8 
    Total deferred tax assets   8,097    7,012 
    Valuation allowance   (8,097)   (7,012)
    Deferred tax liabilities:          
    Total deferred tax liabilities   -    - 
    Net deferred taxes   -    - 

      

    C.Theoretical tax:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
                 
    Loss before taxation   (11,053)   (11,286)   (14,976)
    Theoretical tax credit at applicable statutory rate: 23%   (2,542)   (2,596)   (3,444)
    Non-allowable expenses   (391)   (244)   (1,026)
    Temporary differences and tax losses for which no Deferred Tax Asset is recognized   (2,151)   (2,352)   (2,418)
    Income tax benefit   -    -    - 

     

    F-29

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 17 – SHARE-BASED PAYMENT:

     

    1.On March 24, 2022, the Company’s board of directors (“Board of directors”) approved a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company’s advisory board members and an additional consultant. The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date.

     

    2.On March 24, 2022, the Company’s Board of Directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares. The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual life of the options under the 2019 Equity Incentive Plan is ten years.

     

    3.On April 6, 2022, the Company’s Board of Directors approved a grant of 285,713 fully vested RSUs to an officer.

     

    4.On May 19, 2022, the Company’s Board of Directors approved a grant of 30,000 RSUs to an employee. The RSUs vest over a period of three years, with a 1-year cliff period, commencing on the grant date.

     

    5.On November 22, 2022, the Company’s Board of Directors approved a grant of 165,000 RSUs to employees. The RSUs vest over a period of three years, with a 1-year cliff period, commencing on the grant date.

     

    6.On January 22, 2024, the Company’s Board of Directors approved a grant of 320,000 RSUs to employees and a grant of options to purchase 80,000 shares to consultants. The RSUs represents the right to receive Ordinary Shares at a future time, 245,000 of which vest over a period of three years, with a one-year cliff period and 70,000 vesting immediately on the grant date. 10,000 of the options were vested immediately on the grant date, 25,000 option vest over a period of three years and 45,000 option vests over a period of one year and nine months. The RSUs designated to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

     

    7.On February 5, 2024, the Company’s Board of Directors approved a grant of 2,277,000 RSUs to officers, a grant of options to purchase 30,000 Ordinary Shares and 90,000 RSUs to directors. The RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of three years, with a one-year cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

      

    The fair value of all granted options was estimated by using the Black Scholes option pricing model, which was aimed to model the value of the Company’s assets over time. The simulation approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions.

     

    The following inputs were used to measure the fair value of the option at grant date:

      

         March 24,
    2022
      January 22,
    2024
      February 5,
    2024
    (i) Expected volatility  52%  144.83%  143.98%
    (ii) Dividend rate  0%  0%  0%
    (iii) Expected term (vesting period)  Three years  Three years  Three years
    (iv) Contractual life  Ten years  Ten years  Ten years
    (v) Free risk rate  2.79%-2.80%  4.03%-4.07%  4.16%

     

    F-30

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 17 – SHARE-BASED PAYMENT (CONT.):

     

    The fair value of all granted RSUs was the Company’s quote price at the grant date.

     

    During the year ended December 31, 2024, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount of $1,767.

     

    During the year ended December 31, 2023, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount of $1,427.

     

    During the year ended December 31, 2022, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount of $4,879.

      

    The options to services providers and advisers outstanding as December 31, 2024, 2023 and 2022 were as follows:

     

       Year ended
    December 31, 2024
       Year ended
    December 31, 2023
       Year ended
    December 31, 2022
     
       Number of
    options
       Weighted
    average
    Exercise
    price NIS
       Number of
    options
       Weighted
    average
    Exercise
    price NIS
       Number of
    options
       Weighted
    average
    Exercise
    price NIS
     
                             
    Outstanding at beginning of year   105,111    4.085    114,512    3.058    87,833    0.37 
    Reclassified to employees and directors   -    -    -    -    -    - 
    Granted   80,000    3.779    -    -    29,400    10.84 
    Exercised   -    -    9,401    0.367    (2,721)   0.37 
    Forfeited   -    -    -    -    -    - 
    Options outstanding   185,111    3.359    105,111    4.085    114,512    3.058 
    Options exercisable   162,154    3.251    94,242    3.267    82,257    0.37 
    Share-based payment expenses  $66        $19        $54      

     

    The RSUs to services providers and advisers outstanding as of December 31, 2024, 2023 and 2022 were as follows:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
       Number of
    RSUs
       Number of
    RSUs
       Number of
    RSUs
     
    Outstanding at beginning of year   7,433    18,266    10,000 
    Granted   -    -    22,500 
    Vested   7,433    10,833    14,234 
    RSUs outstanding   -    7,433    18,266 
    RSU’s Vested   32,500    25,067    14,234 
    Share-based payment expenses  $1   $9   $33 

     

    F-31

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 17 - SHARE BASED PAYMENT (CONT.):

     

    The options to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as follows:

     

       Year ended
    December 31, 2024
       Year ended
    December 31, 2023
       Year ended
    December 31, 2022
     
       Number of
    options
       Weighted
    average
    Exercise
    price NIS
       Number of
    options
       Weighted
    average
    Exercise
    price NIS
       Number of
    options
       Weighted
    average
    Exercise
    price NIS
     
                             
    Outstanding at beginning of year   357,689    0.37    386,260    0.37    448,120    0.37 
    Granted   30,000    3.56    -    -         - 
    Exercised   19,048    0.37         0.37    4,309    0.37 
    Forfeited   -    -    28,571    0.37    57,551    0.37 
    Options outstanding   368,641    0.70    357,689    0.37    386,260    0.37 
    Options exercisable   338,641    0.45    350,131    0.37    342,757    0.37 
    Share-based payment expenses  $17        $47    -   $174    - 

     

    The RSUs to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as follows:

     

       Year ended
    December 31,
    2024
       Year ended
    December 31,
    2023
       Year ended
    December 31,
    2022
     
       Number of
    RSUs
       Number of
    RSUs
       Number of
    RSUs
     
    Outstanding at beginning of year   445,140    1,727,842    2,002,587 
    Granted   2,687,000    -    1,016,854 
    Forfeited   25,836    67,087    65,626 
    Vested   587,508    1,215,615    1,225,973 
    RSUs outstanding   2,518,796    445,140    1,727,842 
    RSU’s Vested   3,684,697    3,097,189    1,881,574 
    Share-based payment expenses  $1,683   $1,352   $4,618 

      

    F-32

     

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    NOTES TO FINANCIAL STATEMENTS

    In thousands $ (except share and per share data)

     

    NOTE 18 - RELATED PARTIES:

     

    The following transactions arose with related parties

     

    Transactions and balances with related parties:

     

      1. Shareholders and other related parties’ benefits

     

       December 31,
    2024
       December 31,
    2023
       December 31,
    2022
     
    Salary and related expenses – officers and directors   1,710    1,761    1,923 
    Share based payment – officers and directors   1,376    1,009    3,745 

     

      2. Balances with related parties

     

    Name  Nature of transaction  December 31,
    2024
       December 31,
    2023
     
    Officers  Salaries and related   (381)   (314)
    Directors  Compensation for directors   (40)   (40)

      

    NOTE 19 - SUBSEQUENT EVENTS:

     

    1.Following the closing of the December Private Placement, $70 was wired to the Company from one of the investors before the end of the year but was registered by the receiving bank in January 2025. As a result, $70 were not included in the cash and cash equivalent as of December 31, 2024. The private offering fees and other related expenses in the amount of $220 were paid by the Company after the end of the year.

     

    2.During January and February 2025, the Company received funds in the amount of NIS 238,122 (approximately $66) from the IIA.

     

    3.On February 20, 2025, the Company’s Board of Directors approved a grant of 676,000 RSUs to employees and options to purchase an aggregate of 50,000 Ordinary Shares to service providers under the 2019 Equity Incentive Plan. 20,166 RSUs are vested as of the date of these Financial Statements. None of the total amount of the options are vested as of the date of these Financial Statements. The total grant fair value is approximately $656 that will be registered as expenses in the upcoming vesting period of three years.

     

    4.On February 20, 2025, the Company’s Board of Directors approved a grant of 550,000 RSUs to certain of its executives. None of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $494 that will be registered as expenses in the upcoming vesting period of three years.

     

    5.On February 20, 2025, the Company’s Board of Directors approved a grant of 1,810,000 RSUs to certain of its executives. The approval is subject to shareholder approval. None of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $1.6 million that will be registered as expenses in the upcoming vesting period of three years.

     

     

    F-33

    U.S. GAAP P3Y P10Y 0001837493 true FY P3Y P3Y P10Y P10Y 0001837493 2024-01-01 2024-12-31 0001837493 dei:BusinessContactMember 2024-01-01 2024-12-31 0001837493 iinn:OrdinarySharesNoParValueMember 2024-01-01 2024-12-31 0001837493 iinn:WarrantsToPurchaseOrdinarySharesMember 2024-01-01 2024-12-31 0001837493 2024-12-31 0001837493 2023-12-31 0001837493 2023-01-01 2023-12-31 0001837493 2022-01-01 2022-12-31 0001837493 us-gaap:CommonStockMember 2023-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001837493 us-gaap:RetainedEarningsMember 2023-12-31 0001837493 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001837493 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001837493 us-gaap:CommonStockMember 2024-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001837493 us-gaap:RetainedEarningsMember 2024-12-31 0001837493 us-gaap:CommonStockMember 2022-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001837493 us-gaap:RetainedEarningsMember 2022-12-31 0001837493 2022-12-31 0001837493 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001837493 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001837493 us-gaap:CommonStockMember 2021-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001837493 us-gaap:RetainedEarningsMember 2021-12-31 0001837493 2021-12-31 0001837493 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001837493 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001837493 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001837493 2024-04-01 2024-04-01 0001837493 2024-04-01 0001837493 us-gaap:CommonStockMember 2024-06-14 2024-06-14 0001837493 iinn:PreFundedWarrantsMember 2024-06-14 0001837493 iinn:PreFundedWarrantsMember 2024-06-14 2024-06-14 0001837493 2024-06-14 0001837493 iinn:JunePreFundedWarrantsMember 2024-06-14 0001837493 2024-06-14 2024-06-14 0001837493 iinn:JunePlacementAgentWarrantsMember 2024-06-14 2024-06-14 0001837493 iinn:DecemberPrivatePlacementMember 2024-12-27 2024-12-27 0001837493 iinn:DecemberPrivatePlacementMember 2024-12-27 0001837493 iinn:DecemberPreFundedWarrantsMember 2024-12-27 2024-12-27 0001837493 iinn:PreFundedWarrantsMember 2024-12-27 0001837493 iinn:DecemberPreFundedWarrantsMember 2024-12-27 0001837493 us-gaap:WarrantMember 2024-12-27 2024-12-27 0001837493 2024-12-27 2024-12-27 0001837493 2024-12-27 0001837493 srt:WeightedAverageMember 2024-12-31 0001837493 us-gaap:ComputerEquipmentMember 2024-01-01 2024-12-31 0001837493 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001837493 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-01-01 2024-12-31 0001837493 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-01-01 2024-12-31 0001837493 us-gaap:LeaseholdImprovementsMember 2024-01-01 2024-12-31 0001837493 iinn:BankLeumiMember 2024-12-31 0001837493 country:US 2024-12-31 0001837493 iinn:BankLeumiMember 2023-12-31 0001837493 country:US 2023-12-31 0001837493 country:IL 2023-12-31 0001837493 us-gaap:ComputerEquipmentMember 2023-12-31 0001837493 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001837493 iinn:RDEquipmentMember 2023-12-31 0001837493 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001837493 iinn:RDEquipmentMember 2024-01-01 2024-12-31 0001837493 us-gaap:FurnitureAndFixturesMember 2024-01-01 2024-12-31 0001837493 us-gaap:ComputerEquipmentMember 2024-12-31 0001837493 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001837493 iinn:RDEquipmentMember 2024-12-31 0001837493 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001837493 us-gaap:ComputerEquipmentMember 2022-12-31 0001837493 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001837493 iinn:RDEquipmentMember 2022-12-31 0001837493 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001837493 us-gaap:ComputerEquipmentMember 2023-01-01 2023-12-31 0001837493 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0001837493 iinn:RDEquipmentMember 2023-01-01 2023-12-31 0001837493 us-gaap:FurnitureAndFixturesMember 2023-01-01 2023-12-31 0001837493 2019-09-01 2019-09-30 0001837493 2019-09-30 0001837493 2023-10-31 2023-10-31 0001837493 srt:MinimumMember 2024-12-31 0001837493 srt:MaximumMember 2024-12-31 0001837493 iinn:December2024PrivatePlacementMember 2023-01-01 2023-12-31 0001837493 iinn:December2024PrivatePlacementMember 2023-12-31 0001837493 iinn:December2024PrivatePlacementMember 2024-01-01 2024-12-31 0001837493 iinn:December2024PrivatePlacementMember 2024-12-31 0001837493 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-12-31 0001837493 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001837493 us-gaap:CommonStockMember 2023-12-26 2023-12-26 0001837493 iinn:PrivateWarrantsMember 2023-12-26 0001837493 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001837493 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001837493 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001837493 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001837493 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001837493 us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001837493 us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001837493 us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001837493 iinn:PrivateWarrantsMember 2024-12-31 0001837493 iinn:PrivateWarrantsMember 2023-12-31 0001837493 iinn:PrivateWarrantsMember 2024-12-31 0001837493 iinn:PrivateWarrantsMember 2023-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001837493 iinn:RothCapitalPartnersLLCMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001837493 iinn:RegisteredDirectOfferingMember us-gaap:CommonStockMember 2023-12-26 2023-12-26 0001837493 2023-12-26 0001837493 iinn:PreFundedWarrantsMember 2023-12-26 0001837493 srt:MaximumMember iinn:PreFundedWarrantsMember 2023-12-26 0001837493 srt:MinimumMember iinn:PreFundedWarrantsMember 2023-12-26 0001837493 iinn:PreFundedWarrantsMember 2023-12-31 0001837493 iinn:PreFundedWarrantsMember 2024-01-01 2024-12-31 0001837493 iinn:RegisteredDirectOfferingMember 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001837493 iinn:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2024-12-31 0001837493 iinn:PlacementAgentWarrantsMember 2024-12-31 0001837493 iinn:PlacementAgentWarrantsMember 2024-01-01 2024-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001837493 iinn:TwoThousandTwentyFourAprilOfferingMember 2024-04-01 2024-04-01 0001837493 iinn:TwoThousandTwentyFourAprilOfferingMember 2024-04-01 0001837493 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-05-20 0001837493 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-05-20 2024-05-20 0001837493 iinn:TwoThousandTwentyFourJuneOfferingMember 2024-06-14 2024-06-14 0001837493 iinn:TwoThousandTwentyFourJuneOfferingMember 2024-06-14 0001837493 srt:MaximumMember iinn:JunePreFundedWarrantsMember 2024-06-14 0001837493 srt:MinimumMember iinn:JunePreFundedWarrantsMember 2024-06-14 0001837493 iinn:JunePreFundedWarrantsMember 2024-06-14 2024-06-14 0001837493 iinn:JunePreFundedWarrantsMember 2024-01-01 2024-12-31 0001837493 iinn:TwoThousandTwentyFourJuneOfferingMember 2024-01-01 2024-12-31 0001837493 iinn:TwoThousandTwentyFourJuneOfferingMember 2024-12-31 0001837493 iinn:JunePreFundedWarrantsMember 2024-12-31 0001837493 iinn:JunePlacementAgentWarrantsMember 2024-12-31 0001837493 iinn:JunePlacementAgentWarrantsMember 2024-01-01 2024-12-31 0001837493 iinn:JunePlacementAgentWarrantsMember 2024-06-14 0001837493 2024-06-30 2024-06-30 0001837493 iinn:DecemberPrivateWarrantsMember 2024-12-27 2024-12-27 0001837493 iinn:DecemberPrivateWarrantsMember us-gaap:CommonStockMember 2024-12-27 0001837493 iinn:DecemberPrivateWarrantsMember 2024-12-27 0001837493 srt:MaximumMember iinn:DecemberPrivateWarrantsMember 2024-12-27 0001837493 srt:MinimumMember iinn:DecemberPreFundedWarrantsMember 2024-12-27 0001837493 iinn:DecemberPrivateWarrantsMember us-gaap:CommonStockMember 2024-12-27 2024-12-27 0001837493 us-gaap:IPOMember 2024-01-01 2024-12-31 0001837493 iinn:DecemberPrivateOfferingMember 2024-12-31 0001837493 iinn:DecemberPrivateOfferingMember 2024-01-01 2024-12-31 0001837493 iinn:December2024PrivatePlacementMember 2024-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001837493 us-gaap:CommonStockMember 2024-12-31 0001837493 us-gaap:CommonStockMember 2023-12-31 0001837493 us-gaap:WarrantMember 2023-12-31 0001837493 us-gaap:WarrantMember 2023-12-31 2023-12-31 0001837493 us-gaap:WarrantMember 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice55Member 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice55Member 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice55TwoMember 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice55TwoMember 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember iinn:Exercise6875Member 2024-12-31 0001837493 us-gaap:WarrantMember iinn:Exercise6875Member 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePriceOnePointSixMember 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePriceOnePointSixMember 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice156Member 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice156Member 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePriceOnePointOneMember 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePriceOnePointOneMember 2024-01-01 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice0001Member 2024-12-31 0001837493 us-gaap:WarrantMember iinn:ExercisePrice0001Member 2024-01-01 2024-12-31 0001837493 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001837493 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001837493 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001837493 country:IL 2024-01-01 2024-12-31 0001837493 country:IL 2023-01-01 2023-12-31 0001837493 srt:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-24 0001837493 iinn:AdvisoryBoardMembersMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-24 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-03-24 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-03-24 2022-03-24 0001837493 srt:BoardOfDirectorsChairmanMember 2022-03-24 0001837493 iinn:MedicalBoardMembersMember 2022-03-24 0001837493 us-gaap:StockOptionMember 2022-03-24 2022-03-24 0001837493 2022-03-24 2022-03-24 0001837493 iinn:TwoThousandNineteenEquityIncentivePlanMember 2022-03-24 2022-03-24 0001837493 srt:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2022-04-06 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-05-19 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-05-19 2022-05-19 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-11-22 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-11-22 2022-11-22 0001837493 us-gaap:EmployeeStockMember 2024-01-22 0001837493 us-gaap:EmployeeStockMember 2024-01-22 2024-01-22 0001837493 us-gaap:RestrictedStockUnitsRSUMember us-gaap:EmployeeStockMember 2024-01-22 0001837493 2024-01-22 0001837493 2024-01-22 2024-01-22 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2024-01-22 2024-01-22 0001837493 us-gaap:StockOptionMember 2024-01-22 2024-01-22 0001837493 srt:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001837493 srt:OfficerMember 2024-02-05 2024-02-05 0001837493 srt:OfficerMember us-gaap:StockOptionMember 2024-02-05 2024-02-05 0001837493 srt:DirectorMember 2024-02-05 0001837493 2024-02-05 2024-02-05 0001837493 iinn:EmployeesDirectorsAndSubcontractorsMember 2024-01-01 2024-12-31 0001837493 iinn:EmployeesDirectorsAndSubcontractorsMember 2023-01-01 2023-12-31 0001837493 iinn:EmployeesDirectorsAndSubcontractorsMember 2022-01-01 2022-12-31 0001837493 srt:MinimumMember 2022-03-24 2022-03-24 0001837493 srt:MaximumMember 2022-03-24 2022-03-24 0001837493 srt:MinimumMember 2024-01-22 2024-01-22 0001837493 srt:MaximumMember 2024-01-22 2024-01-22 0001837493 iinn:ServicesProvidersAndAdvisersMember 2023-12-31 0001837493 iinn:ServicesProvidersAndAdvisersMember 2022-12-31 0001837493 iinn:ServicesProvidersAndAdvisersMember 2021-12-31 0001837493 iinn:ServicesProvidersAndAdvisersMember 2024-01-01 2024-12-31 0001837493 iinn:ServicesProvidersAndAdvisersMember 2023-01-01 2023-12-31 0001837493 iinn:ServicesProvidersAndAdvisersMember 2022-01-01 2022-12-31 0001837493 iinn:ServicesProvidersAndAdvisersMember 2024-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2023-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2022-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2021-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2024-01-01 2024-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2023-01-01 2023-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2022-01-01 2022-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2024-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001837493 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001837493 iinn:OfficersAndDirectorsMember 2024-01-01 2024-12-31 0001837493 iinn:OfficersAndDirectorsMember 2023-01-01 2023-12-31 0001837493 iinn:OfficersAndDirectorsMember 2022-01-01 2022-12-31 0001837493 srt:OfficerMember 2024-01-01 2024-12-31 0001837493 srt:OfficerMember 2023-01-01 2023-12-31 0001837493 srt:DirectorMember 2024-01-01 2024-12-31 0001837493 srt:DirectorMember 2023-01-01 2023-12-31 0001837493 iinn:DecemberPrivatePlacementMember 2024-01-01 2024-12-31 0001837493 us-gaap:SubsequentEventMember 2025-01-01 2025-01-01 0001837493 us-gaap:SubsequentEventMember 2025-02-28 2025-02-28 0001837493 us-gaap:SubsequentEventMember us-gaap:EmployeeStockMember 2025-02-20 2025-02-20 0001837493 iinn:TwoThousandNineteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2025-02-20 2025-02-20 0001837493 iinn:ExecutivesMember us-gaap:SubsequentEventMember 2025-02-20 2025-02-20 0001837493 us-gaap:SubsequentEventMember 2025-02-20 2025-02-20 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:ILS iso4217:ILS xbrli:shares
    Get the next $IINN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients

      RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures.  As part of this advancement, Inspira will deploy the U.S. Food and Drug Administration ("FDA") approved INSPIRA ART100 system at one of Israel's renowned medical centers affiliated with the largest health care provider. A team of pioneeri

      5/7/25 8:45:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

      RA'ANANA, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ technology. This breakthrough innovation is uniquely designed to oxygenate blood effectively without the trauma associated with conventional hollow fiber technologies. The in vivo testing achieved above 99% gas exchange target at a defined flow rate. The VORTX technology, slated for integration into Inspira's pipeline, including the INSPIRA ART500, aims to transform acute respiratory ca

      4/23/25 8:00:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

      RA'ANANA, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, April 15, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received payment from its U.S. distributor, Glo-Med Networks Inc. ("Glo-Med"), for a delivery of its INSPIRA™ ART100 systems, which are cleared by the U.S. Food & Drug Administration ("FDA"). The revenue, in the range of the low hundreds of thousands of dollars, relates to the delivery of the INSPIRA ART100 systems, which have been recently installed at a premier U.S. academic medical center, as previously announced. In addition

      4/15/25 9:15:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    SEC Filings

    See more
    • SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

      6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

      5/7/25 9:15:16 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

      6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

      4/23/25 8:05:13 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

      6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

      4/15/25 9:20:03 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

      SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

      11/14/24 4:08:42 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

      SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

      2/14/24 3:40:01 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

      SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

      2/12/24 4:05:09 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    See more

    $IINN
    Financials

    Live finance-specific insights

    See more
    • PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

      Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

      2/6/25 8:27:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

      RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.     Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated

      1/21/25 8:30:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

      RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the

      12/11/23 9:00:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

      Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

      3/11/25 8:30:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira™ Announces Business Plan Targets

      Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today.     On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's

      6/20/24 9:25:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector

      The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024. This event provides the Company with an opportunity to present the system in front of healthcare representa

      6/5/24 8:30:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

      Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      11/1/21 12:39:26 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

      Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

      8/26/21 10:05:11 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care